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Abstract 
Background: A grafted donor liver should grow and survive under the different 
conditions presented by a liver transplantation recipient. It has remained unclear, 
however, whether the age of a grafted liver can be modulated by recipient factors.  
Aims: This study investigated whether a grafted aged donor liver can be rejuvenated in 
a pediatric recipient.  
Methods: Of 119 living donor liver transplants, 10 pairs have been adult-to-pediatric 
combinations. Senescence Marker Protein-30 (SMP30), which is a protein that is 
remarkably reduced upon aging, was used as a senescence marker. 
Immunohistochemical staining for SMP30 was performed in biopsy specimen after 
LDLT. Re-expression of SMP30 was investigated in a biopsied adult liver (n=6) that 
had been transplanted in a pediatric recipient. 
Results: A remarkable expression of SMP30 was seen in a control pediatric normal liver 
in comparison with that in an aged adult donor biopsy. Re-expression or an increase in 
SMP-30 was not observed in the liver of any pediatric recipient who had received an 
adult liver. 
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Conclusion:  An adult grafted liver does not appear to rejuvenate in a pediatric 
recipient.  
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Introduction  
Many investigators have reported worse outcomes of orthotopic liver transplantation 
(OLT) with aged donor liver graft 1)2). Especially since living donor liver transplantation 
(LDLT) is performed with a partial liver graft, lower patient survival has been reported 
with senile donor grafts than with graft from younger donors 3). However, if grafted 
aged liver could adapt to the environment of young or pediatric recipients, resulting in 
rejuvenation, an aged grafted liver could be regarded as a young graft through the life of 
the recipient as observed in vitro experiment 4). However, no report of rejuvenation of 
graft liver in humans has been made thus far.  
 Senescence Marker Protein-30 (SMP30) was found in the liver of rats and is 
reported to markedly decrease through the senescence process 5、6). SMP-30 is 
associated with Vitamin C synthesis 7), and it has been reported that the senescence 
process proceeds four times faster in SMP-30 knock-out mouse than in normal mouse 8). 
Thus SMP30 is one of the key elements of senescence. It has also been reported that 
when SMP30 decreases, resistance to infectious pathogens would decrease along with 
organ function, resulting in aging of the organs 9-11). 
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 We therefore used this unique protein expression in the liver to clarify whether 
a grafted liver can successfully become rejuvenated in adult-to-pediatric LDLT.  
 
Patients and Methods 
Of 119 living donor liver transplants up until March 2010, 10 pediatric liver 
transplantations were performed with grafts obtained from parents of the recipients. 
Eleven biopsies were performed in the 6 patients, when it was clinically indicated.  
Afterwards, re-expression of SMP30 was investigated in a biopsied adult liver (n=6) 
that had been transplanted in a pediatric recipient. Characteristics of recipients and 
donors are described in Table 1. 
 
Methods of LDLT 
 LDLT methods have been reported elsewhere12). All partial liver grafts were 
preserved in University of Wisconsin solution and implanted using a piggy-back 
technique. A dual or triple immunosuppressive regimen was used that included 
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tacrolimus or cyclosporine A, steroid, and mycophenolate mofetil. Biopsy-proven 
rejections were treated if clinical and laboratory signs mandated steroid bolus treatment.  
 
Immunohistochemical staining for SMP30 
 Four-micrometer liver sections were deparaffinized and rehydrated through 
100%, 95%, and 90% ethanol. In terms of the heat-induced antigen retrieval protocol, a 
40-minute treatment with Target Retrieval Solution (code S2031, DAKO, Carpinteria, 
CA) was followed by a 20-minute cool-down period at room temperature. The tissue 
sections were then immunostained using an automated staining system (Autostainer 
Plus, DAKO, Carpinteria, CA). Slides were incubated with an anti-SMP30 polyclonal 
antibody (1:80 dilution, code SML-ROI001,SHIMA Laboratories) for 30 minutes at 
room temperature and subsequently with Histofine Simple Stain MAX-PO (MULTI) 
(Nichirei, Japan). Incubation was performed overnight at 4 degrees Celsius, followed by 
a wash in three changes of PBS for 5 minutes. For all staining, the reaction product was 
developed with the use of 3-diaminobenzidine tetra hydrochloride and H2O2. The 
sections were counterstained with Meyer hematoxylin-Eosin. Visualization was labeled 
polymer (EnVision+ system; code K4001,Dako) for 30 minutes at room temperature, 
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3,3′-diaminobenzidine as a chromogen for 5 minutes, and hematoxylin as a counterstain 
for 5 minutes.  
 Among stained hepatocytes, semiquantification was performed based on the 
comparison with positive controls and negative controls.  Positivity of staining was 
classified as follows; negative-: weak+/-: moderate +; strong ++. 
 
Results 
 Remarkable expression of SMP30 was seen in a control pediatric liver (10 
years old, male, normal liver obtained at liver resection for hepatoblastoma, Fig. 1A, B) 
and 2 other pediatric patients (3 years old, patient with neuroblastoma; 1 year old, 
patient with hepatoblastoma). On the other hand, very limited expression of SMP30 was 
observed in a case of senile liver (64 years old, male, living donor, Fig. 1C, D), which 
can be regarded as a negative control.  
 Fig. 2A depicts diseased liver explanted for liver transplantation in a 1-year-old 
female (Case 2). Even in a diseased liver due to biliary atresia, SMP30 was expressed 
(Fig. 2A, B). At the time of liver transplantation, the graft liver did not express SMP30 
(37 years old, mother, Fig. 3). After the graft liver was transplanted into the recipient, a 
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series of liver biopsies was performed. Four and 5 years after the LDLT, no increase in 
SMP30 in the liver was observed (Fig. 3A-D). Similarly, in the other pediatric recipient 
for LDLT, SMP30 was not increased over time (Fig. 4A,B: 40 years old living donor, 
Fig. 4C,D: 5 years after the LDLT, Case 4).  
 The results of the immunohistochemical staining for SMP30 are summarized in 
Table 1. No re-expression of SMP30 was observed in any of the cases. 
 
Discussion 
 In this study, we clearly demonstrated no re-expression of a senescent marker, 
SMP30 in aged liver graft transplanted in pediatric patients. This is the first literature 
report indicating that no rejuvenation of a graft occurs after liver transplantation based 
on SMP30. 
 With regard to the relationship between aging and liver function, it has been 
reported that liver function is not altered in the aging process 13), while Hyams has 
reported a slight derangement of liver function in aged patients 14). Some investigators 
have also reported that with aging, drug metabolism of propranolol decreases in 
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hepatocytes of the liver based on an in vitro experiment 15). On the other hands, a 
relationship between aging and liver regeneration has been reported in vitro, with DNA 
synthesis in the hepatocytes of aged rats decreasing but with a preserved repair process 
as compared with that seen in young rats 16). As to in vivo experiments, there have been 
some reports indicating a decrease or delay (24 hours) in DNA synthesis after partial 
hepatectomy in elderly rats 17,18).  Tsukamoto et al. have reported a 24-hour delay in 
liver regeneration with aged, 60-week-old rats compared with 6-week-old rats 19) . 
 In the field of liver transplantation, rejuvenation of the liver has not been fully 
investigated. Sakai et al. have reported that the survival rate after OLT is similar 
between aged (28 months old) and young rats (5 months old) 20). However, it has been 
revealed that fibrosis, bile duct proliferation, and pigment deposition are more observed 
in aged grafts than in young rats, implying that the liver function of aged liver grafts 
could be bearable but that the aging process is indeed advancing. Recently, Selzner et al. 
have reported that in the rat model with ischemia reperfusion injury, apoptosis induced 
by TNF-α is increased in aged rats compared with young rats 21). This mechanism might 
be one of the causes of poor graft function in an aged liver graft. 
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 On the other hand, Conboy et al. have reported the rejuvenation of aged 
progenitor cells in response to exposure to a young systematic environment 4). In this 
experiment, it was also reported that old hepatocytes can be rejuvenated in a serum of 
young rats in terms of DNA synthesis and Ki67 expression, suggesting the possible 
rejuvenation of hepatocytes. 
 With regard to hepatocyte proliferation, SMP30 has a suppressive effect on cell 
proliferation in the SMP30 knock-out mouse model 22). However, many reports have 
indicated that SMP30 overexpression can decrease reactive oxygen species and exert a 
cytoprotective effect 23). In addition, the possible involvement of apoptosis reduction 
has been reported 24).  Other than the liver, decreases in SMP30 are related to organ 
dysfunction such as that of the brain, ear, and lung 25-27). If SMP30 expression is 
increased in grafted aged liver, the graft survival rate after OLT with aged donor liver 
could be as good as that with young donor liver.  
 SMP30 was used as a marker for senescence in the present study because it is 
ubiquitously expressed in pediatric liver and is stable for immunohistochemical 
investigations of paraffin-fixed samples. Another possible marker of senescence is the 
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telomere length, although a huge number of samples is needed to determine whether 
there are differences in telomere length, making this method impractical. 
 In conclusion, it was demonstrated in humans that rejuvenation, as assessed by 
SMP30, was not observed in the setting of adult-to-pediatric liver transplantation. 
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Fig. 1: Immunohistochemical staining for SMP30 
A (x40), B (X200): Positive control: 10 years old, male, normal liver taken form 
patients with hepatoblastoma. 
C (x40), D (x200): Negative control: 64 years old, male, live donor 
EGUCHI et al. 
19 
 
Fig. 2: Immunohistochemical staining for SMP30 (Case 2) 
A (x40), B (X100): 1 year old, female, biliary atrasia 
C (x40), D (x100): 37 years old, mother, live donor 
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Fig. 3: Immunohistochemical staining for SMP30 (Case 2) 
 1 year old, female, biliary atrasia after living donor liver transplantation 
A (x40), B (X100): 4 years after LDLT（5 years old） 
C (x100), D (x100): 5 years after LDLT （6 years old） 
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Fig. 4: Immunohistochemical staining for SMP30 (Case 4) 
A (x40), B (X100): 40 years old, mother, live donor 




Table 1. Immunohistochemical staining for SMP-30 
No Age/Relation  SMP-30 Age /Primary disease Liver biopsy SMP-30
(time after LDLT)
1 40/Mother - 6/Biliary atresia 2M -
2Y -
8Y -
2 40/Mother + 1/Biliary atresia Explant +
4Y +
5Y +/-
3 37/Mother - 5/Biliary atresia 7Y -
8Y -
4 40/Mother + 11M/Biliary atresia Explant +  
5Y +/-
5 37/Mother - 7M/Fulminant hepatic failure 2Y -
3Y -
6 35/Father - 10M/Biliary atresia 0.5Y -
SMP-30
C t l 10Y/H t bl t (N l li ) ++on ro s epa o as oma orma  ver
3Y/Neuroblastoma (Normal liver) ++
1Y/Hepatoblastoma (Normal liver) ++
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